Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Concept and progress in the development of RGD-containing peptide pharmaceuticals

W S Craig1, S Cheng, D G Mullen

  • 1Telios Pharmaceutical, Inc., San Diego, California 92121.

Biopolymers
|January 1, 1995
PubMed
Summary

Synthetic peptides utilizing the arginine-glycine-aspartic acid (RGD) cell adhesion domain show promise as drug agents. These RGD peptides act as antagonists for integrin alpha IIb beta 3 and promote tissue integration for medical implants.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MiR-485-3p and miR-485-5p suppress breast cancer cell metastasis by inhibiting PGC-1α expression.

Cell death & disease·2016
Same author

Association between RAGE gene polymorphisms and ulcerative colitis susceptibility: a case-control study in a Chinese Han population.

Genetics and molecular research : GMR·2016
Same author

Prevention of esophageal stricture after endoscopic submucosal dissection: a systematic review and meta-analysis.

Surgical endoscopy·2015
Same author

Identification of natural recombinants derived from PCV2a and PCV2b.

Genetics and molecular research : GMR·2015
Same author

Important co-morbidity in patients with diabetes mellitus in three clinics in Western Kenya.

Public health action·2015
Same author

Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma.

Genetics and molecular research : GMR·2015

Area of Science:

  • Biochemistry
  • Materials Science
  • Pharmacology

Background:

  • The arginine-glycine-aspartic acid (RGD) motif is a key cell adhesion domain.
  • Synthetic peptides can be engineered to act as either drug antagonists or agonists.
  • Integrin alpha IIb beta 3 is a critical target for modulating platelet aggregation.

Purpose of the Study:

  • To develop potent and specific RGD-containing peptides as antagonists for integrin alpha IIb beta 3.
  • To design RGD peptides that can modify medical implant surfaces to enhance biocompatibility.
  • To investigate both antagonist and agonist activities of engineered RGD peptides.

Main Methods:

  • Cell-based and integrin-based assays were employed to screen for antagonist activity.
  • Comparative molecular modeling was used to identify key pharmacophoric features.

Related Experiment Videos

  • Surface modification assays and in vivo studies assessed the agonist activity and biocompatibility of implant-associated peptides.

    • Main Results:

    • Highly potent and integrin-specific RGD antagonist peptides with reduced side effects were identified.
    • A novel RGD peptide was developed that noncovalently modifies synthetic material surfaces.
    • This surface-modifying peptide demonstrated agonist activity, stimulating cell attachment and improving in vivo tissue integration.

    Conclusions:

    • Engineered RGD peptides offer versatile therapeutic potential, acting as specific integrin antagonists.
    • RGD peptide surface modification of medical implants enhances cellular interaction and promotes faster tissue integration.
    • These findings suggest a new strategy for improving the performance and biocompatibility of medical devices.